. 2015 Jan 7;29(2):167–174. doi: 10.1097/QAD.0000000000000519

Table 2.

Significant factors in multivariable regression models of each endpoint.

			1^st endpoint: snapshot				2^nd endpoint: time to TRDF				2^nd endpoint: time to ERDF
Effect	Group	Comparator	RD (% points)	CI	P	P_int	HR	95% CI	P	P_int	HR	95% CI	P	P_int
Age
	≥ 36 years	< 36	3.8	(1.2, 6.5)	0.005	0.80	–		–		–		–
Baseline viral load
	> 100k	≤ 100k	− 7.6	(−11.2, − 4.1)	< 0.001	0.02	1.9	(1.38, 2.69)	< 0.001	0.028	3.1	(2.01, 4.92)	< 0.001	0.632
Race
	White	Non-white	4.3	(0.7, 7.9)	0.018	0.93	–		–		–		–
Third agent
	DRV/r	DTG	− 5.0	(−9.8, − 0.1)	0.044	NA	2.4	(0.73, 7.68)	0.153	NA	–		–
	EFV	DTG	− 7.0	(−11, − 3)	< 0.001		2.5	(1.54, 4.08)	< 0.001		–		–
	RAL	DTG	− 2.2	(−5.7, 1.3)	0.226		1.4	(0.82, 2.29)	0.223		–		–
CD4 + cell count (cells/μl)
	200 to < 350	≥ 350	− 1.5	(−4.5, 1.5)	0.313	0.24	1.5	(1.02, 2.15)	0.039	< 0.001	1.4	(0.85, 2.44)	0.177	0.801
	< 200	≥ 350	− 5.6	(−10.9, − 0.2)	0.041		2.3	(1.47, 3.49)	< 0.001		3.5	(2.03, 5.87)	< 0.001
Hepatitis coinfection
	Hep B/C	Neither/missing	− 7.6	(−14.4, − 0.8)	0.028	0.36	–		–		–		–
Risk factor
	Homosexual sex	Neither	5.04	(1.8, 8.3)	0.002	0.88	–		–		–		–
	IVDU	Neither	− 7.3	(−18.6, 4)	0.208		–		–		–		–
Study
	SINGLE	FLAMINGO	–		–		3.0	(1.03, 8.64)	0.044	NA	4.3	(1.51, 12.06)	0.006	NA
	SPRING-2	FLAMINGO	–		–		3.5	(1.22, 10.06)	0.020		6.5	(2.35, 18.06)	< 0.001

DRV/r, darunavir/ritonavir; DTG, dolutegravir; EFV, efavirenz; HR, hazard ratio; IVDU, intravenous drug use; P_int, P value for an interaction between each covariate and treatment; RAL, raltegravir; RD, risk difference.